课题基金 / 基金详情

Core C: Genome Engineering Core

Core C: Genome Engineering Core
核心 C:基因组工程核心
批准号:
10006187
负责人:
Bruce R Conklin
金额:
$28.35万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-01 至 2024-08-31

项目摘要

项目成果

Bruce R Conklin的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT CORE C – GENOME ENGINEERING CORE Core C is focused on providing the most up-to-date genome engineering technology for studies of cardiac development. We will develop and adopt emerging technology for CRISPR/Cas9-mediated gene deletions, single-base changes, transgene insertions, and epigenetic remodeling. The PPG proposal utilizes advanced genome engineering techniques. We will specifically provide genome engineering services of human iPSCs to efficiently deliver engineered iPSCs for cardiac differentiation. The Genome Engineering Core will also provide epigenome editing methods, that modify the cell's genome without cutting DNA. The CRISPR- associated nuclease (Cas9) has been modified so that the nuclease is inactive in making “dCas” that can now be used to carry and localize a wide variety of bioactive molecules to any location in the genome. We pioneered the use of CRISPRi that silences gene expression in iPSCs, and are involved in developing better methods that activate gene expression (CRISPRa). Our team is an established leader in genome engineering, and has made efforts to improve every aspect of genome editing in human iPSCs to benefit the PPG investigators in their efforts to unravel the molecular basis of congenital heart disease. In the last 5 years, we made >50 different genetically modified human iPSC lines with point mutations that exactly mimic the disease mutations, generate insertions/deletions (indels) for gene knockouts, or introduce endogenous gene tags for molecular studies of protein function (Miyaoka et al., 2014, Huebsch et al., 2015, Mandegar et al., 2016, Judge et al., 2017). The Genome Engineering Core will adopt the latest methods for genome engineering, such as the use of CRISPR/Cas9 RNP-protein complexes (RNP) to introduce insertion/deletions (indels), or delete discrete portions of genes to inactivate them in iPSCs as well as in iPSC-derived cardiomyocytes, since RNP-mediated genome editing is more efficient and accurate in our experience. In addition, the Genome Engineering Core will provide genome engineering services for the insertion of transgenes at endogenous loci, as well as develop new CRISPR methods for the PPG investigators to further investigate the cardiac interactome. The Genome Engineering Core will develop a pipeline to deliver high-quality engineered iPSCs to the PPG projects with continuously updated techniques, to answer vital questions in heart development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
C9orf72 frontotemporal dementia (FTD) and amyotrophic lateral sclerosis(ALS): using patient cells and CRISPR to reveal therapeutic approaches
  • 批准号:
    10590420
  • 项目类别:
  • 资助金额:
    $23.93万
  • 财政年份:
    2021
  • 负责人:
    Bruce R Conklin
  • 依托单位:
C9orf72 frontotemporal dementia (FTD) and amyotrophic lateral sclerosis(ALS): using patient cells and CRISPR to reveal therapeutic approaches
  • 批准号:
    10186371
  • 项目类别:
  • 资助金额:
    $212.63万
  • 财政年份:
    2021
  • 负责人:
    Bruce R Conklin
  • 依托单位:
Core C: Genome Engineering Core
  • 批准号:
    10245028
  • 项目类别:
  • 资助金额:
    $28.35万
  • 财政年份:
    2019
  • 负责人:
    Bruce R Conklin
  • 依托单位:
Core C: Genome Engineering Core
  • 批准号:
    10471986
  • 项目类别:
  • 资助金额:
    $28.35万
  • 财政年份:
    2019
  • 负责人:
    Bruce R Conklin
  • 依托单位:
海外基金